



Universiteit
Leiden
The Netherlands

Imatinib in patients with severe COVID-19: a randomised, doubleblind, placebo-controlled, clinical trial (vol 9, pg 957, 2021)

Aman, J.; Duijvelaar, E.; Botros, L.; Kianzad, A.; Schippers, J.R.; Smeele, P.J.; ... ; Bogaard, H.J.

Citation

Aman, J., Duijvelaar, E., Botros, L., Kianzad, A., Schippers, J. R., Smeele, P. J., ... Bogaard, H. J. (2021). Imatinib in patients with severe COVID-19: a randomised, doubleblind, placebo-controlled, clinical trial (vol 9, pg 957, 2021). *The Lancet Respiratory Medicine*, 9(8), E82-E82. doi:10.1016/S2213-2600(21)00283-6

Version: Publisher's Version

License: [Creative Commons CC BY 4.0 license](#)

Downloaded from: <https://hdl.handle.net/1887/3566366>

Note: To cite this publication please use the final published version (if applicable).

**Correction to
Lancet Respir Med 2021;
published online
June 17, [https://doi.org/10.1016/S2213-2600\(21\)00237-X](https://doi.org/10.1016/S2213-2600(21)00237-X)**

Aman J, Duijvelaar E, Botros L, et al. Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial. Lancet Respir Med 2021; published online June 17. [https://doi.org/10.1016/S2213-2600\(21\)00237-X](https://doi.org/10.1016/S2213-2600(21)00237-X)—In this Article, the authors Elisabeth C W Neefjes', Jeroen N Wessel's, Carolina C Pamplona's, and Elise M A Slob's names were incorrect. Rianne J A Hoek's affiliation should have been "Department of Pulmonary Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, VUMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands". These corrections have been made to the online version as of June 25, 2021, and will be made to the printed version.



Published Online
June 25, 2021
[https://doi.org/10.1016/S2213-2600\(21\)00283-6](https://doi.org/10.1016/S2213-2600(21)00283-6)